Fresenius Kabi launches Velcade alternative
Fresenius Kabi has introduced its alternative of Takeda Oncology’s Velcade (bortezomib for injection). The Lake Zurich, Ill.-based company said that this addition to its oncology offerings is the first available alternative for intravenous use.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
“Fresenius Kabi bortezomib is a cost-efficient product alternative for our customers and the patients they treat,” Fresenius Kabi USA president and CEO John Ducker said. “We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines”
Fresenius Kabi’s product is indicated to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior treatment.
According to Takeda’s quarterly filings, Velcade has had U.S. sales of $60.2 million for the first two quarters of its fiscal year 2017. For the full fiscal year 2016, Takeda reported $112.9 million in U.S. sales for Velcade.
With strong flu season on horizon, Rite Aid urges flu shots
With the Centers for Disease Control and Prevention reporting widespread flu activity in 46 states, Rite Aid on Thursday urged people to get vaccinated against the flu if they haven’t already done so.
“With the CDC reporting widespread flu activity, health experts are predicting that the 2017-2018 flu season will be one of the worst in recent history,” stated Jocelyn Konrad, Rite Aid executive vice president of pharmacy.
[quote-from-article] “As we enter the peak of flu season, it’s not too late for people who haven’t been vaccinated against the flu to do so," she noted. "Though it takes two weeks to gain full protection against the flu, getting a flu shot as soon as possible is the single best way to fight the flu and the vaccine also helps to ease the severity and duration of symptoms if you come down with the flu.”
The CDC estimates the flu will infect 1-in-5 Americans this year.
With flu typically peaking between December and February, it’s possible for the flu season to run through March, meaning there is still time to get vaccinated.
FDA approves Lupin’s Tamiflu generic
The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.